DE60218302T2 - Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten - Google Patents
Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten Download PDFInfo
- Publication number
- DE60218302T2 DE60218302T2 DE60218302T DE60218302T DE60218302T2 DE 60218302 T2 DE60218302 T2 DE 60218302T2 DE 60218302 T DE60218302 T DE 60218302T DE 60218302 T DE60218302 T DE 60218302T DE 60218302 T2 DE60218302 T2 DE 60218302T2
- Authority
- DE
- Germany
- Prior art keywords
- lymphocytes
- cells
- antigen
- specific
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000000427 antigen Substances 0.000 claims abstract description 55
- 102000036639 antigens Human genes 0.000 claims abstract description 55
- 108091007433 antigens Proteins 0.000 claims abstract description 55
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 20
- 108010084313 CD58 Antigens Proteins 0.000 claims abstract description 17
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 6
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims abstract description 5
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims abstract description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims abstract description 5
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 claims abstract description 5
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 5
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 77
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000003098 myoblast Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000004116 schwann cell Anatomy 0.000 claims description 2
- 210000005233 tubule cell Anatomy 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 abstract description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 29
- 102000003814 Interleukin-10 Human genes 0.000 description 27
- 108090000174 Interleukin-10 Proteins 0.000 description 27
- 229940076144 interleukin-10 Drugs 0.000 description 25
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 206010043376 Tetanus Diseases 0.000 description 6
- 239000003948 anatoxin Substances 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 230000004940 costimulation Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100022339 Integrin alpha-L Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/453—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0106231A FR2824567B1 (fr) | 2001-05-11 | 2001-05-11 | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
| FR0106231 | 2001-05-11 | ||
| PCT/FR2002/001586 WO2002092793A1 (fr) | 2001-05-11 | 2002-05-10 | Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60218302D1 DE60218302D1 (de) | 2007-04-05 |
| DE60218302T2 true DE60218302T2 (de) | 2007-11-15 |
Family
ID=8863160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60218302T Expired - Lifetime DE60218302T2 (de) | 2001-05-11 | 2002-05-10 | Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8076133B2 (enExample) |
| EP (1) | EP1390474B1 (enExample) |
| JP (1) | JP4185366B2 (enExample) |
| AT (1) | ATE354641T1 (enExample) |
| CA (1) | CA2446981C (enExample) |
| DE (1) | DE60218302T2 (enExample) |
| DK (1) | DK1390474T3 (enExample) |
| ES (1) | ES2282425T3 (enExample) |
| FR (1) | FR2824567B1 (enExample) |
| WO (1) | WO2002092793A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358506B1 (en) | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| EP1061949B1 (en) | 1998-03-03 | 2009-07-15 | University of Southern California | Cytokines and mitogens to inhibit graft-versus-host disease |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| CA2469800A1 (en) * | 2001-12-21 | 2003-07-24 | University Of Southern California | Methods for the induction of professional and cytokine-producing regulatory cells |
| WO2003057171A2 (en) * | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7638326B2 (en) * | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| AU2003292137A1 (en) * | 2002-11-29 | 2004-06-23 | Maria Grazia Roncarolo | Rapamycin and il-10 for the treatment of immune diseases |
| FR2852967B1 (fr) * | 2003-03-26 | 2007-12-07 | Txcell | Procede d'obtention de cellules dendritiques et de cellules t |
| FR2856700B1 (fr) * | 2003-06-24 | 2007-06-08 | Txcell | Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications |
| WO2005046729A2 (en) * | 2003-11-12 | 2005-05-26 | Txcell | Use of lipopeptides for activating t lymphocytes through the skin |
| ES2653570T3 (es) | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| US7985409B2 (en) | 2004-08-11 | 2011-07-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Tr1 cells for use in atherosclerosis |
| EP1812563B1 (en) * | 2004-10-29 | 2013-04-10 | Benaroya Research Institute at Virginia Mason | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use |
| EP1712615A1 (en) * | 2005-04-15 | 2006-10-18 | Txcell | In vitro production of a cell population using feeder cells |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| ATE513903T1 (de) * | 2005-07-01 | 2011-07-15 | Txcell S A | Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc |
| EA015989B1 (ru) * | 2005-08-31 | 2012-01-30 | АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ | Лечение воспалительного заболевания кишечника |
| GB0603081D0 (en) * | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| JP5543207B2 (ja) * | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| EP2185936A4 (en) * | 2007-08-02 | 2010-08-04 | Iss Immune System Stimulation | DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE |
| JP5539886B2 (ja) * | 2007-10-17 | 2014-07-02 | ティクセル | Ｔｒ１細胞、間葉系幹細胞およびその使用 |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| EP2062970A1 (en) * | 2007-11-26 | 2009-05-27 | Txcell | Compositions for treating an intestinal inflammatory condition |
| SI2113254T1 (sl) | 2008-04-28 | 2013-01-31 | Txcell | Sestave za zdravljenje vnetnih avtoimunskih stanj |
| EP2113560A1 (en) * | 2008-04-28 | 2009-11-04 | TXCell | Compositions for treating an arthritic condition |
| CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2221364A1 (en) | 2009-02-23 | 2010-08-25 | TXCell | Compositions for treating an allergic or asthmatic condition |
| EP2412802A1 (en) * | 2010-07-29 | 2012-02-01 | TXCell | IL-13 producing TR1-like cells and use thereof |
| EP2439534A1 (en) | 2010-10-08 | 2012-04-11 | TXCell | Method for assessing the efficacy of a TR1 cell therapy in asubject |
| BR112013023968A2 (pt) | 2011-03-25 | 2016-12-13 | Txcell | uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune |
| EP2982746A1 (en) | 2014-08-07 | 2016-02-10 | TXCell | Regulatory T cells with therapeutic potential |
| AU2019269601A1 (en) | 2018-05-17 | 2020-11-26 | Regents Of The University Of Minnesota | Drug-resistant immune cells and methods of use thereof |
| WO2019237378A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 一种将CD274基因定点整合至Jurkat细胞的方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277635B1 (en) * | 1992-03-04 | 2001-08-21 | Schering Corporation | Use of interleukin-10 to produce a population of suppressor cells |
| DE69734974D1 (de) * | 1996-02-08 | 2006-02-02 | Us Gov Health & Human Serv | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen |
| CA2254975C (en) * | 1996-05-23 | 2008-12-16 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells |
| US6746670B2 (en) * | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
| US6670146B2 (en) * | 2000-10-04 | 2003-12-30 | Schering Corporation | Regulatory T cells; methods |
-
2001
- 2001-05-11 FR FR0106231A patent/FR2824567B1/fr not_active Expired - Fee Related
-
2002
- 2002-05-10 JP JP2002589661A patent/JP4185366B2/ja not_active Expired - Fee Related
- 2002-05-10 US US10/477,671 patent/US8076133B2/en not_active Expired - Fee Related
- 2002-05-10 DE DE60218302T patent/DE60218302T2/de not_active Expired - Lifetime
- 2002-05-10 WO PCT/FR2002/001586 patent/WO2002092793A1/fr not_active Ceased
- 2002-05-10 CA CA2446981A patent/CA2446981C/fr not_active Expired - Fee Related
- 2002-05-10 ES ES02740789T patent/ES2282425T3/es not_active Expired - Lifetime
- 2002-05-10 DK DK02740789T patent/DK1390474T3/da active
- 2002-05-10 AT AT02740789T patent/ATE354641T1/de not_active IP Right Cessation
- 2002-05-10 EP EP02740789A patent/EP1390474B1/fr not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/928,189 patent/US20080233095A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1390474A1 (fr) | 2004-02-25 |
| JP4185366B2 (ja) | 2008-11-26 |
| FR2824567A1 (fr) | 2002-11-15 |
| EP1390474B1 (fr) | 2007-02-21 |
| US20080233095A1 (en) | 2008-09-25 |
| CA2446981C (fr) | 2012-03-20 |
| DE60218302D1 (de) | 2007-04-05 |
| ES2282425T3 (es) | 2007-10-16 |
| DK1390474T3 (da) | 2007-07-02 |
| US8076133B2 (en) | 2011-12-13 |
| ATE354641T1 (de) | 2007-03-15 |
| FR2824567B1 (fr) | 2003-08-08 |
| WO2002092793A1 (fr) | 2002-11-21 |
| JP2004526459A (ja) | 2004-09-02 |
| US20040191235A1 (en) | 2004-09-30 |
| CA2446981A1 (fr) | 2003-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60218302T2 (de) | Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten | |
| DE69328481T2 (de) | In vitro bildung von dentritischen zellen | |
| DE60210623T2 (de) | Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen | |
| DE69729455T2 (de) | Methode und zusammensetzungen zum erlangen reifer dendritischer zellen | |
| DE69910362T2 (de) | Anwendung der mesenchymalen stammzellen als immunsuppressiva | |
| DE60026561T2 (de) | Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen | |
| DE69713336T2 (de) | Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren | |
| EP1331944B1 (de) | Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen | |
| DE69534595T2 (de) | Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür | |
| DE69231250T2 (de) | Kombinierte zelluläre und immunsuppressive therapien | |
| US8603815B2 (en) | CD4+ CD25− T cells and Tr1-like regulatory T cells | |
| EP0693120B1 (de) | Tumorizide t-lymphozyten | |
| DE60117167T2 (de) | Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen | |
| DE69012105T2 (de) | Proliferation von cd4-lymfocyten. | |
| DE60130634T2 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
| DE60130206T2 (de) | Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen | |
| DE60016567T2 (de) | Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode | |
| WO2009021995A1 (de) | Verfahren zur in-vitro-amplifikation von regulatorischen t-zellen | |
| DE60038119T2 (de) | Dendritische zellen, aktiviert in anwesenheit von glucocorticoiden hormonen, sind in der lage, die antigenspezifische t-zell-antwort zu unterdrücken | |
| WO1992020783A1 (de) | Verfahren zur bereitstellung von antigen-spezifischen b- und t-lymphozyten sowie davon erhaltene monoklonale antikörper | |
| Goodell et al. | Canine dendritic cells from peripheral blood and lymph nodes | |
| DE102018108996B4 (de) | Verfahren zur Herstellung autologer T-Zellen | |
| DE102019108125B4 (de) | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung | |
| WO1998018907A1 (de) | Verfahren zur herstellung von tumoriziden t-lymphozyten | |
| WO2004009801A1 (de) | Nicht antigen präsentierende zellen zur selektion von t-zellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |